Science and Technology Director Catalent, Inc. Somerset, New Jersey
From understanding your molecule’s ADME and bioavailability challenges to determining an optimal dose form, drug developers encounter many pitfalls from candidate selection to Phase I that can lead the program to stall, stop, or rework. Catalent expert will introduce a fast and efficient development process that can help deliver the right clinical candidate, best formulation strategy and an optimal dosage form to Phase 1. The presentation will discuss in detail data-driven approaches including PBPK modeling, parallel formulation screening, API sparing techniques and optimal early dosing strategies that will help avoid development pitfalls and de-risk path to clinic.
Find out how to utilize PBPK modeling in candidate and formulation selection
Review scalable formulation technologies for poorly soluble compounds
Share API sparing techniques for selecting the best formulation approach and showcase optimal dosing strategies in early development